Carisma Therapeutics News

H.C. Wainwright Downgrades Carisma Therapeutics(CARM.US) to Hold Rating

Moomoo NewsDec 16 07:31 ET

CARISMA Therapeutics Analyst Ratings

BenzingaDec 12 14:43 ET

Carisma Therapeutics Price Target Cut to $1.00/Share From $10.00 by Baird

Dow JonesDec 12 06:00 ET

Baird Downgrades Carisma Therapeutics(CARM.US) to Hold Rating, Cuts Target Price to $1

Moomoo NewsDec 12 05:32 ET

BTIG Maintains Carisma Therapeutics(CARM.US) With Hold Rating

Moomoo NewsDec 12 05:32 ET

Carisma Therapeutics: Hold Rating Amid Strategic Shift and Uncertain Pipeline Prospects

TipRanksDec 12 05:00 ET

Carisma Therapeutics Cut to In-Line From Outperform by Evercore ISI Group

Dow JonesDec 11 12:29 ET

Carisma Therapeutics Price Target Cut to $0.70/Share From $4.00 by Evercore ISI Group

Dow JonesDec 11 12:29 ET

Evercore Downgrades Carisma Therapeutics(CARM.US) to Hold Rating, Cuts Target Price to $0.7

Moomoo NewsDec 11 08:31 ET

Carisma Therapeutics Cut to Neutral From Buy by BTIG

Dow JonesDec 10 13:03 ET

BTIG Downgrades Carisma Therapeutics(CARM.US) to Hold Rating

Moomoo NewsDec 9 17:31 ET

BTIG Downgrades Carisma Therapeutics (CARM) to a Hold

TipRanksDec 9 16:37 ET

CARISMA Therapeutics Analyst Ratings

BenzingaNov 18 16:44 ET

Carisma Therapeutics Is Maintained at Buy by D. Boral Capital

Dow JonesNov 11 17:21 ET

Carisma Therapeutics Price Target Maintained With a $24.00/Share by D. Boral Capital

Dow JonesNov 11 17:21 ET

Optimistic Buy Rating for Carisma Therapeutics Amid Promising CAR-Myeloid Developments and Strong Financial Standing

TipRanksNov 11 01:16 ET

Evercore Maintains Carisma Therapeutics(CARM.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsNov 8 09:38 ET

Evercore ISI Remains a Buy on Carisma Therapeutics (CARM)

TipRanksNov 8 09:21 ET

CARISMA Therapeutics Analyst Ratings

BenzingaNov 7 08:34 ET

EF Hutton Initiates Coverage On CARISMA Therapeutics With Buy Rating, Announces Price Target of $24

BenzingaOct 30 09:16 ET